Section 1 of Japan's Ministry of Health, Labour and Welfare Guideline on Sales Information Activities for Prescription Drugs (abbreviated MSA-G) is the foundation that supports everything that follows. Its three subsections — Purpose, Scope of Application, and Basic Principles — establish the framework within which all subsequent, more specific provisions are interpreted. They are short but consequential: they define what the guideline treats as a problem, who it addresses, and what range of activities it covers.
The MSA-G emerged because three categories of conduct were falling through the gaps of existing regulation: verbal explanations that leave no documentary trace, information provision that falls short of outright false claims but nudges toward off-label or otherwise inappropriate use, and the supply of research papers and other content in ways that obscure the company's involvement. Pharmaceutical Act Article 66 and the Industry Code on Fair Promotion were not designed to reach these grey zones. Section 1 puts the problem into writing.
01What the Purpose Clause Reveals About Regulatory Gaps
Japan's Pharmaceutical and Medical Device Act (PMD Act) imposes labeling obligations and prohibits false or exaggerated advertising under Article 66. Industry self-regulatory codes add further detail. But when a medical representative conveys information verbally in a consultation room, nothing is recorded. When a journal reprint is handed over "as a reference," it is genuinely unclear whether that constitutes an advertisement. When promotional information emphasizes efficacy in ways that encourage inappropriate use, Article 66 may not be triggered if no outright falsehood is present.
The MSA-G was drafted to fill those gaps. The purpose clause in Section 1-1 states that the guideline aims to "ensure the appropriate use of prescription drugs and contribute to the improvement of public health," positioning it as a complement to, not a substitute for, existing regulation.
So what: The MSA-G is not simply a stricter version of pharmaceutical advertising law. It is a separate regulatory instrument targeting three distinct grey zones — unrecorded verbal activity, misleading-but-not-false promotion, and content whose company origin is obscured. Reading Section 1-1 provides the diagnostic question: does this conduct fall into any of those three categories?
So why: Existing rules were designed around "demonstrably false or exaggerated" claims. Real-world problematic conduct typically takes the form of "true but misleading" or "said but unverifiable." A separate instrument was needed to address conduct that existing rules could not reach.
02The Scope Clause: Who, What, and How Far
Section 1-2 defines who bears responsibility under the guideline, what conduct is covered, and which types of materials are in scope. Marketing authorization holders, co-promotion partners, and wholesale distributors are all included. The guideline applies regardless of job title — whether a person is called an MR, an MSL, or something else, if they are involved in sales-oriented information provision, they are covered. The definition of "materials" is deliberately broad, encompassing oral explanations and electronic content alongside printed documents.
Each company and related industry body is also required to establish its own internal rules based on the MSA-G, including voluntary commitments that go beyond its minimum requirements. The guideline sets a floor, not a ceiling.
So what: Internal rules, contracts with outsourced vendors, and co-promotion agreements all need to be reviewed against this scope logic. The guideline cannot be read as applying only to a company's own directly employed MRs.
So why: Problematic conduct has historically occurred through outsourced parties and co-promotion arrangements. Limiting coverage to direct employees would have reproduced the very gap the guideline was intended to close.
03How Section 1 Shapes the Reading of Everything That Follows
The provisions in Sections 2 and beyond — covering material review processes, the substantive requirements for information content, and the management of relationships with healthcare institutions — are all written against the background established in Section 1. The reason Section 2's material review requirements extend to verbal explanations is that Section 1-2 defines oral communication as a "material." The reason Section 3's evidentiary requirements are demanding is that Section 1-1 identified misleading-but-not-false promotion as the core problem.
Reading individual provisions without having absorbed Section 1 tends to produce rule-following at the level of literal text, which increases the risk of misjudging grey-zone situations. Section 1 is, in effect, the interpretive key to the entire guideline.
So what: Before concluding that a particular activity is permissible because it is not explicitly prohibited, the compliance question to ask is: does this conduct fall within the category of behaviour Section 1 identifies as the problem the guideline was written to address?
So why: Regulatory evasion almost always occurs in the space between explicit prohibitions. Codifying the purpose and problem context in Section 1 narrows the credibility of "it's not literally prohibited" arguments.
Section 1 has three subsections: what the problem is and what the guideline aims to achieve (Purpose); who is subject to it and what conduct and materials are covered (Scope); and the principles that guide interpretation of all subsequent provisions (Basic Principles). Internalizing this structure means reading Sections 2 and beyond not as a compliance checklist but as a coherent set of instruments aimed at a specific problem. For practitioners, this matters most in grey-zone situations — where the answer depends on purpose and context, not just literal text.